Trabedersen (AP 12009) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2 , such as those of the skin, pancre
Storage Temp
Store at -20°C,Desiccated
Shipped In
Ice chest + Ice pads
Product Description
Trabedersen (AP 12009) is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad). Trabedersen can be used for the study of malignant brain tumors and other solid tumors overexpressing TGF-β2 , such as those of the skin, pancreas and colon.
In Vitro
Trabedersen (1-80 μM; 7 days) reduces TGF-β2 secretion in human pancreatic cancer cell line Hup-T3 with an IC 50 in the low μM range, clearly inhibits cell proliferation, and completely blocks migration of pancreatic cancer cells. Trabedersen reverses TGF-β2-mediated immunosuppression of pancreatic cancer cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Hup-T3 cells Concentration: 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM, 60 μM, 80 μM Incubation Time: 7 days Result: Inhibited cell proliferation, and completely blocked migration of pancreatic cancer cells.
In Vivo
Trabedersen (initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week; i.p.) treatment significantly reduces tumor growth, lymph node metastasis and angiogenesis in an orthotopic mouse model of metastatic pancreatic cancer. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Eight-week-old male athymic nude mice (BALB⁄Cnu ⁄nu) bearing human pancreatic cancer cells. Dosage: Initial loading dose of 50 mg/kg bodyweight followed by 16 mg/kg three times a week. Administration: Intraperitoneal (i.p.) injection; three times a week; for 27 days Result: Significantly reduced tumor growth, lymph node metastasis and angiogenesis.
